This page is for archiving purposes only; several methodological guidelines created under EUnetHTA activities have been reworked and adapted for the joint work under the HTA regulation.
| Title | Version | Last update | Link |
|---|---|---|---|
| Comparators & Comparisons - Criteria for the choice of the most appropriate comparator(s) | 2.0 | 2015 | PDF Version |
| Comparators & Comparisons - Direct and indirect comparisons | 2.0 | 2015 | PDF Version |
| Endpoints used for Relative Effectiveness Assessment - Clinical Endpoints | 2.0 | 2015 | PDF Version |
| Endpoints used for Relative Effectiveness Assessment - Composite endpoints | 2.0 | 2015 | PDF Version |
| Endpoints used for Relative Effectiveness Assessment - Health related quality of life and utility measures | 2.0 | 2015 | PDF Version |
| Endpoints used in Relative Effectiveness Assessment - Safety | 2.0 | 2015 | PDF Version |
| Endpoints used in Relative Effectiveness Assessment - Surrogate Endpoints | 2.0 | 2015 | PDF Version |
| Internal validity of non-randomised studies (NRS) on interventions | 1.0 | 2015 | PDF Version |
| Internal validity of randomised controlled trials | 2.0 | 2015 | PDF Version |
| Levels of Evidence – Applicability of evidence for the context of a relative effectiveness assessment | 2.0 | 2015 | PDF Version |
| Meta-analysis of diagnostic test accuracy studies | 1.0 | 2014 | PDF Version |
| Methods for health economic evaluations – A guideline based on current practices in Europe | 1.0 | 2015 | PDF Version |
| Personalised Medicine and Co-Dependent Technologies | 1.0 | 2015 | PDF Version |
| Practical considerations when critically assessing economic evaluations | 1.0 | 2020 | PDF Version |
| Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness | 2.0 | 2019 | PDF Version |
| Therapeutic medical devices | 1.0 | 2015 | PDF Version |